| |
| |
|
| Insider
Information: |
Smith Karen L. |
| Relationship: |
Chief Medical Officer |
| City: |
Dublin 4 |
| State: |
L2 |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
6 |
|
| Direct
Shares |
291,713 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$4,183,129 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
291,713 |
|
|
| Total
Value |
$4,183,129 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Jazz Pharmaceuticals Inc |
JAZZ |
EVP, R&D and CMO |
2018-03-05 |
28,474 |
2015-05-11 |
0 |
Premium* |
|
|
Acceleron Pharma Inc |
XLRN |
Director |
2021-04-01 |
4,561 |
2018-03-01 |
0 |
Premium* |
|
|
Sangamo Biosciences Inc |
SGMO |
Director |
2023-06-01 |
52,100 |
2018-06-26 |
0 |
Premium* |
|
|
Antares Pharma Inc |
ATRS |
Director |
2022-05-24 |
0 |
2019-06-13 |
0 |
Premium* |
|
|
Emergent Biosolutions Inc. |
EBS |
EVP, Chief Medical Off... |
2021-05-07 |
11,888 |
2021-02-24 |
0 |
Premium* |
|
|
Cortexyme, Inc. |
CRTX |
Chief Medical Officer |
2022-05-19 |
194,690 |
2022-05-19 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| SGMO |
Sangamo Biosciences Inc |
Director |
– • – |
2023-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
13,900 |
52,100 |
0 |
- |
|
| ATRS |
Antares Pharma Inc |
Director |
– • – |
2022-05-24 |
4 |
D |
$5.60 |
$446,012 |
D/D |
(79,645) |
0 |
0 |
- |
|
| CRTX |
Cortexyme, Inc. |
Chief Medical Officer |
• – – |
2022-05-19 |
4/A |
A |
$0.00 |
$0 |
D/D |
170,354 |
194,690 |
0 |
- |
|
| CRTX |
Cortexyme, Inc. |
Chief Medical Officer |
• – – |
2022-05-19 |
4 |
A |
$0.00 |
$0 |
D/D |
24,336 |
24,336 |
0 |
- |
|
| SGMO |
Sangamo Biosciences Inc |
Director |
– • – |
2022-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
12,500 |
38,200 |
0 |
- |
|
| ATRS |
Antares Pharma Inc |
Director |
– • – |
2021-06-10 |
4 |
A |
$4.42 |
$112,498 |
D/D |
25,452 |
79,645 |
0 |
- |
|
| EBS |
Emergent Biosolutions Inc... |
EVP, Chief Medical Officer |
• – – |
2021-05-07 |
4 |
D |
$60.85 |
$18,559 |
D/D |
(305) |
11,888 |
0 |
- |
|
| XLRN |
Acceleron Pharma Inc |
Director |
– • – |
2021-04-01 |
4 |
OE |
$35.34 |
$363,405 |
D/D |
8,925 |
13,486 |
0 |
- |
|
| XLRN |
Acceleron Pharma Inc |
Director |
– • – |
2021-04-01 |
4 |
AS |
$134.54 |
$1,218,003 |
D/D |
(8,925) |
4,561 |
0 |
% |
|
| SGMO |
Sangamo Biosciences Inc |
Director |
– • – |
2021-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
8,200 |
25,700 |
0 |
- |
|
| EBS |
Emergent Biosolutions Inc... |
EVP, Chief Medical Officer |
• – – |
2021-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
5,883 |
12,193 |
0 |
- |
|
| XLRN |
Acceleron Pharma Inc |
Director |
– • – |
2021-01-29 |
4 |
A |
$0.00 |
$0 |
D/D |
1,622 |
4,561 |
0 |
- |
|
| ATRS |
Antares Pharma Inc |
Director |
– • – |
2020-06-11 |
4 |
A |
$2.73 |
$82,501 |
D/D |
30,220 |
54,193 |
0 |
- |
|
| SGMO |
Sangamo Biosciences Inc |
Director |
– • – |
2020-05-18 |
4/A |
A |
$0.00 |
$0 |
D/D |
10,000 |
17,500 |
0 |
- |
|
| SGMO |
Sangamo Biosciences Inc |
Director |
– • – |
2020-05-18 |
4 |
A |
$0.00 |
$0 |
D/D |
2,500 |
10,000 |
0 |
- |
|
| XLRN |
Acceleron Pharma Inc |
Director |
– • – |
2020-01-22 |
4 |
A |
$0.00 |
$0 |
D/D |
1,377 |
2,939 |
0 |
- |
|
| ATRS |
Antares Pharma Inc |
Director |
– • – |
2019-06-13 |
4 |
A |
$2.92 |
$70,001 |
D/D |
23,973 |
23,973 |
0 |
- |
|
| SGMO |
Sangamo Biosciences Inc |
Director |
– • – |
2019-06-10 |
4 |
A |
$0.00 |
$0 |
D/D |
2,500 |
7,500 |
0 |
- |
|
| XLRN |
Acceleron Pharma Inc |
Director |
– • – |
2019-01-25 |
4 |
A |
$0.00 |
$0 |
D/D |
1,250 |
1,562 |
0 |
- |
|
| SGMO |
Sangamo Biosciences Inc |
Director |
– • – |
2018-06-26 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
5,000 |
0 |
- |
|
| JAZZ |
Jazz Pharmaceuticals Inc |
EVP, R&D and CMO |
• – – |
2018-03-05 |
4 |
D |
$143.39 |
$92,917 |
D/D |
(648) |
28,474 |
0 |
- |
|
| XLRN |
Acceleron Pharma Inc |
Director |
– • – |
2018-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
312 |
312 |
0 |
- |
|
| JAZZ |
Jazz Pharmaceuticals Inc |
EVP, R&D and CMO |
• – – |
2018-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
29,122 |
0 |
- |
|
| JAZZ |
Jazz Pharmaceuticals Inc |
EVP, R&D and CMO |
• – – |
2017-05-11 |
4 |
A |
$0.00 |
$0 |
D/D |
1,000 |
21,527 |
0 |
- |
|
| JAZZ |
Jazz Pharmaceuticals Inc |
EVP, R&D and CMO |
• – – |
2017-05-11 |
4 |
D |
$155.18 |
$99,470 |
D/D |
(641) |
20,527 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
